Novel Coronavirus Information Center

Elsevier’s free health and medical research on novel coronavirus (2019-nCoV)

Welcome to Elsevier's Novel Coronavirus Information Center.

Margaret Hessen, MD, Director, Point of Care, ElsevierA week in late January has shown us (again) how rapidly a new disease can take root and spread. Such events are accompanied by an explosion of clinical and epidemiological information and research. The goal of this website is to open whatever resources we can to help public health authorities, researchers and clinicians contain and manage this disease. We will provide continually updated resources from Elsevier's content and experts. Our resources span scientific and medical journals and textbooks, educational products, and a variety of other resources, like travel precautions from the CDC and media posts of interest to our community.

The site is curated by clinical experts from our Global Health business and updated frequently to keep pace with evolving knowledge.

If you're looking for information on our other free and low-cost access programs, including resources for patients and caregivers, you can find that here.

Margaret Trexler Hessen, MD
Director, Point of Care
Elsevier


Expert guidance and commentary

Key facts for clinicians

By Margaret Trexler Hessen, MD | January 27, 2020

Background: In December, China notified the World Health Organization of several cases of human respiratory illness, which appeared to be linked to an open seafood and livestock market in the city of Wuhan. The infecting agent has since been identified as a novel coronavirus, now called 2019-nCoV. Although the virus is presumed zoonotic in origin, person-to-person spread is evident. Cases have now been reported in many other areas of China and in other countries in Asia, Europe, the Asia Pacific and North America. Although travel within China has been restricted, and screening of travelers is being implemented in other countries, it is anticipated that more cases will be seen both inside China and internationally.

Novel coronaviruses have emerged as human pathogens in the past, notably associated with outbreaks of SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome). Current investigative methods and recommendations derive in some part from the experience of those epidemics.

Clinical presentation: The incubation period is thought to be 2 to 14 days. Symptoms include fever (which may be absent in persons at extremes of age or with immunocompromise), cough and dyspnea. Chest radiographs may show bilateral infiltrates. Clinical illness varies from mild to severe; about 25% of confirmed cases have been classified as severe, and there are increasing numbers of deaths. In early cases, mortality was associated with advanced age or comorbidities.

Diagnosis: Although respiratory infections (including influenza) are prevalent in the northern hemisphere during the winter, clinicians should inquire about travel history in persons presenting with respiratory illness. The possibility of 2019-nCoV infection should be suspected in persons who present with compatible clinical illness and exposure history. The US Centers for Disease Control (CDC) and World Health Organization (WHO) have slightly different criteria for whom to test, as noted below:

  • Recent travel (within 14 days) from Wuhan, Hubei Province, China (WHO, CDC).
  • Close contact with a person suspected or known to have infection due to 2019-nCoV (WHO, CDC). The CDC defines close contact as being within 6 feet (2 meters) or within a room or care area for a prolonged period without personal protective equipment OR having direct contact with secretions of a person with 2019-nCoV infection.
  • Exposure to a healthcare facility in a country where hospital-associated nCoV infections have been reported (WHO).
  • The disease occurs in a healthcare worker who has been working in an environment where patients with severe acute respiratory infections are being cared for, without regard to place of residence or history of travel (WHO).
  • The person develops an unusual or unexpected clinical course, especially sudden deterioration despite appropriate treatment, without regard to place of residence or history of travel, even if another etiology has been identified that fully explains the clinical presentation (WHO).

In the United States, suspected cases should be reported immediately to local or state health departments, which will determine whether the patient meets clinical and epidemiologic criteria for disease and coordinate diagnostic testing of suspected patients through the CDC. Collection of specimens from the upper respiratory tract, lower respiratory tract and serum is recommended as a priority; other specimens, such as stool or urine, may be collected and stored to be tested at the discretion of the CDC. The CDC provides detailed information on collection and shipping of specimens for cases approved by local or state authorities. The CDC advised that testing for other respiratory pathogens by the provider should be done as part of the initial evaluation and should not delay specimen shipping to CDC.

If a patient with suspected 2019-nCoV infection tests positive for another respiratory pathogen, after clinical evaluation and consultation with public health authorities, they may no longer be considered a person under investigation.

Management: No specific antiviral agent is available for treatment of this infection, and there is no vaccine. Treatment is supportive and includes supplemental oxygen and conservative fluid management, as indicated by clinical condition. WHO provides detailed guidance on such supportive measures and cautions that severely ill patients should be treated empirically for other possible causes while diagnostic test results are pending.

Infection control measures are an integral part of management. Precautions should be instituted as soon as 2019-nCoV infection is suspected:

  • Provide the patient with a face mask and place the patient in a closed room (preferably with structural safeguards against airborne transmission).
  • Persons entering the room should follow standard, contact, and airborne precautions.
  • Patients managed at home are encouraged to self-isolate to a single area of the house (preferably with a separate bathroom) and to wear a face mask during any contact with household members.
  • The patient and all household members should follow diligent hand and cough hygiene.

Complications: Respiratory failure and septic shock occur in some patients. The case fatality rate is about 3 percent.

Margaret Trexler Hessen, MD, is an infectious disease specialist with 20 years of clinical practice experience and public health service, including outbreak management. She has been with Elsevier since 2010 and is currently Director, Point of Care.


Listen to a podcast by Guardian Science Weekly


Clinicians need reliable and current information to combat novel coronavirus

By Jonathan Temte, MD, PhD | January 27, 2020

Jonathan Temte, MD, PhD, Consultant, PracticeUpdate, ElsevierCoronaviruses are incredibly diverse, found in many animal species, and are commonly encountered in clinical practice during the cold and flu season, yet many primary care clinicians are not familiar with these respiratory pathogens. We rarely test for them, and when we do it’s usually when we’re looking for something else. Moreover, we have no specific treatments for these viruses.

The usual suspects have funny names: coronavirus HKU1, NL63, 229E and OC43. In our ongoing surveillance and epidemiological studies in school, clinics and longterm care settings, we find all four of these. There are two other coronaviruses that have been previously shown to infect humans: SARS (severe acute respiratory syndrome-associated coronavirus, or SARS-CoV), which emerged in 2003, and MERS (Middle East Respiratory Syndrome Coronavirus, or MERS-CoV), which emerged in 2012. SARS and MERS are associated with high case fatality rates.

Now a novel coronavirus, named 2019-nCoV, has emerged in China. There are hundreds of cases in China and multiple cases across the globe. The second case in the US was confirmed Friday in Illinois. We are extremely early in this rapidly expanding outbreak. With this evolving situation comes fear, misinformation and many unknowns. Accordingly, clinicians need to find reliable and current sources of credible information. A good place to start is the CDC resource page for healthcare professionals.

Jonathan Temte, MD, PhD, is Associate Dean for Public Health and Community Engagement and Professor of Family Medicine and Community Health at the University of Wisconsin School of Medicine and Public Health and former Chair of the Advisory Committee on Immunization Practices (ACIP). Jon currently serves as Chair of the Wisconsin Council on Immunization Practices and has been active on pandemic influenza and bioterrorism working groups for the state. He is a consultant for Elsevier's PracticeUpdate.


Elsevier Clinical Solutions

We've selected content from Clinical Solutions Nursing, Interprofessional Practice and Patient Education collections to share what we know to date about the novel coronavirus.

Patient engagement resources

Patient engagement resources use plain language to support shared decision-making between patients and healthcare providers. The goal is to deliver the right message in the right way at the time the patient is most ready to learn. The following resources provide an overview of the novel coronavirus to help patients and their families understand their risk, identify signs and symptoms, and prevent it from spreading:

Clinical Skills for Nursing

Clinical Skills for Nursing provides the highest quality evidence for nursing practice procedures for nurses to care for patients. Our Isolation Precautions and Personal Protective Equipment checklists align with CDC and OSHA guidelines:

Interprofessional Care Plans

These Interprofessional Care Plans provide an evidence-based and individualizable Interprofessional plan of care to manage fever and the possible development of pneumonia, which is consistent with the presentation of this virus. Using an interprofessional approach to patient care that aligns current evidence with the individual needs of the patient results in improved patient care outcomes.


中文资源 (Chinese-language resources)

Title Published by (CN) Published by (EN) Link
Virology 
2019新型冠状病毒信息库   National Genomics Data Center

https://bigd.big.ac.cn/ncov

新型冠状病毒国家科技资源服务系统。共享:
1)第一株病毒毒种信息及其电镜照片
2)新型冠状病毒核酸检测引物和探针序列
国家微生物科学数据中心和国家病原微生物资源库 National Microbiological Data Center;
National Pathogen Resource Collection Center
http://nmdc.cn/#/nCoV
Diagnosis & Treatment Guidelines
新型冠状病毒感染的肺炎诊疗方案(试行第三版)(PDF可下载) 国家卫生健康委员会 National Health Commission http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml
湖北省新型冠状病毒感染的肺炎诊疗方案(试行第一版) 湖北省医疗救治专家组 Medical Expert Panel of Hubei Province https://xw.qq.com/cmsid/20200123A0KNOW00
《新型冠状病毒肺炎诊疗快速指南》 华中科技大学同济医学院附属同济医院专家组 Tongji Hospital, Tongji Medical College of HUST https://xw.qq.com/health/20200124010910/HLH2020012401091000
《武汉协和医院处置2019新型冠状病毒感染策略及说明》 华中科技大学同济医学院附属协和医院专家组 Xiehe Hospital, Tongji Medical College of HUST https://www.dxy.cn/bbs/newweb/pc/post/42662254
关于“新型冠状病毒感染的肺炎”诊疗建议方案(V2.0) 中国医学科学院北京协和医院 Peking Union Medical College Hospital, CAMS https://new.qq.com/omn/HLH20200/HLH2020012501009300.html
Research articles and book chapters
Notes from the Field: An Outbreak of NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province...[2020-01-22] 中国疾病预防控制中心 Chinese Center for Disease Control and Prevention http://weekly.chinacdc.cn/en/article/id/e3c63ca9-dedb-4fb6-9c1c-d057adb77b57 
A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019-2020[2020-01-21] 中国疾病预防控制中心 Chinese Center for Disease Control and Prevention http://weekly.chinacdc.cn/en/article/id/a3907201-f64f-4154-a19e-4253b453d10c
中国新型冠状病毒感染病例首批临床数据报告(解读, The Lancet  Weichat Official Account The Lancet Weichat Official Account https://marlin-prod.literatumonline.com/pb-assets/Lancet/marketing/wechat/WeChat_website.jpg
引自《默里及纳达尔呼吸医学》,V Courtney Broaddus 主编,李为民、程德云主译,人民卫生出版社,2018 李为民、程德云主译,人民卫生出版社,2018 Elsevier, with content quoted from translation published by PMPH

Influenza

Pneumonia

Coronavirus

Patient Education
轻症疑似2019新型冠状病毒患者及密切接触人员如何进行自我管理 北京协和医院呼吸科 Respiratory Department, Peking Union Medical College Hospital, CAMS http://m.sohu.com/a/368777653_102327
《新型冠状病毒感染防护》   Elsevier Clinical Solutions 新型冠状病毒感染防护》
Institutional Special Reports
国家卫生健康委员会新型冠状病毒感染的肺炎专题 国家卫生健康委员会 National Health Commission http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml
中国疾病预防控制中心新型冠状病毒感染的肺炎专题 中国疾病预防控制中心 Chinese Center for Disease Control and Prevention http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/
中国疾病预防控制中心周报(English Version) 中国疾病预防控制中心 Chinese Center for Disease Control and Prevention http://weekly.chinacdc.cn/
丁香园丁香热点 丁香园 DingXiangYuan https://www.dxy.cn/bbs/newweb/pc/board/151/3484
Key Media Special Reports
抗击肺炎专题 今日头条 Beijing Byte Dance Technology Co., Ltd. https://www.toutiao.com/
#我在疫情第一线# 三联生活周刊 Sanlian Life Weekly https://s.weibo.com/weibo?q=%23%E6%88%91%E5%9C%A8%E7%96%AB%E6%83%85%E4%B8%80%E7%BA%BF%23&from=default

Research

In this section, you can find the following resources:

The Lancet Coronavirus hub

View this infographic and other coronavirus content on The Lancet's Coronavirus hub.

To assist health workers and researchers working under difficult and dangerous conditions to bring this outbreak to a close, The Lancet has created a Coronavirus hub page. This hub brings together new coronavirus content from The Lancet journals as it is published.


Articles in Elsevier journals

We will be updating this section continually.

More published research

Book chapters


Early-stage research (preprints on SSRN platform)

Emerging and rapidly evolving healthcare emergencies necessitate the quick dissemination of research. The growing role of preprints, or early-stage research, was acknowledged in the Ebola and Zika virus outbreaks as a way of “accelerating the dissemination of scientific findings to support responses to infectious disease outbreaks.

SSRN, Elsevier’s world-leading platform devoted to the rapid worldwide dissemination of early-stage research, is committed to making authors' coronavirus related research available immediately. Research on SSRN is free to download and upload. It is important to note that these papers have not benefited from the pivotal role of the peer-review process, which validates and improves the quality of final published journal articles.


Download this and other infographics for the public from the WHO novel coronavirus website.  Download this and other infographics from the WHO's website Novel Coronavirus advice for the public.Here, you will find official guidance from major health organizations such as the CDC and WHO and media posts of interest to our community.

Official coronavirus guidance from various countries:

Australia | Canada | China | France | Singapore | Spain | UK | US

In the media

  • Coronavirus Hits China Exchange Programs (Inside Higher Ed). Following CDC guidance, colleges are suspending travel to China, a popular destination for faculty and students and a country where many colleges have deep connections.

Contributors


Written by

Elsevier Connect

Written by

Elsevier Connect

This site features daily stories for the global science, health and technology communities, written by experts in the field as well as Elsevier colleagues.